Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

8.4%

222 terminated/withdrawn out of 2635 trials

Success Rate

90.8%

+4.3% vs industry average

Late-Stage Pipeline

24%

630 trials in Phase 3/4

Results Transparency

52%

1144 of 2197 completed trials have results

Key Signals

87 recruiting1144 with results179 terminated43 withdrawn

Enrollment Performance

Analytics

Phase 1
1095(50.5%)
Phase 3
439(20.2%)
Phase 2
382(17.6%)
Phase 4
191(8.8%)
N/A
57(2.6%)
Early Phase 1
4(0.2%)
2168Total
Phase 1(1095)
Phase 3(439)
Phase 2(382)
Phase 4(191)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2635)

Showing 20 of 2635 trials
NCT07304817Phase 2Recruiting

Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

Role: collaborator

NCT06632457Phase 3Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Role: lead

NCT06632444Phase 3Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Role: lead

NCT02783040Phase 1Completed

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Role: lead

NCT07001475Phase 1Recruiting

A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Role: lead

NCT06872892Phase 3Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Role: lead

NCT06745284Phase 1Active Not Recruiting

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Role: lead

NCT07355296Phase 2Recruiting

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

Role: lead

NCT07220083Phase 3Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Role: lead

NCT06424288Phase 3Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Role: lead

NCT06324357Phase 1Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Role: lead

NCT07366034Phase 3Not Yet Recruiting

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease

Role: lead

NCT06151574Phase 3Active Not Recruiting

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Role: lead

NCT07531628Phase 1Not Yet Recruiting

A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants

Role: lead

NCT07409181Phase 2Not Yet Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Role: lead

NCT07201922Phase 3Recruiting

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Role: lead

NCT06926660Phase 2Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Role: lead

NCT06241560Phase 2Recruiting

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Role: lead

NCT07395258Phase 1Recruiting

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Role: lead

NCT06935370Phase 3Recruiting

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Role: lead